Brought to you by 
Xanthus gets US rights to Schering AG's fludarabine
03 Nov 2006
Executive Summary
Xanthus Pharmaceuticals (small-molecule cancer therapeutics) has licensed exclusive US development and marketing rights to Schering AG's (recently acquired by Bayer) Phase III oral fludarabine. Schering already markets the agent in Europe and Canada as Fludara for relapsed B-cell chronic lymphocytic leukemia (CLL).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xanthus gets US rights to Schering AG's fludarabine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice